Divis Laboratories Ltd

The transcript from the Divi's Laboratories Limited Q2 FY24 earnings call does not mention any current or planned fundraising through debt or equity. Key points include: - No discussion or disclosure of new debt or equity issuance. - Capital expenditure is ongoing, particularly for Unit 3 greenfield project, funded internally (INR 263 crores spent on Kakinada project till date). - Cash on hand is substantial (INR 3,604 crores as of September 30, 2023). - Operational expenses for new Unit 3 expected to increase, but no mention of external funding plans. - Management focuses on organic growth and utilization of internal resources. Therefore, as per the latest call transcript, no current or future fundraising through debt or equity is indicated.

- Unit 3 Greenfield Project: A 200-acre Phase I construction project at Kakinada is progressing well. - Production Start: Production activities at Unit 3 are expected to commence towards the end of Q1 FY 2024-25. - Capital Work in Progress: INR 496 crores as of September 30, 2023, with INR 263 crores related to the Kakinada project. - Previous Spend: INR 76 crores spent till the previous year on Kakinada project. - Advances: INR 67 crores in advances for the Kakinada project as of September 2023. - Impact on Expenses: Operational expenses expected to rise as Unit 3 setup completes and production scales up. - Objective: Unit 3 will free up facilities in Units 1 and 2 for new Custom Synthesis and Generic Products opportunities.

- Divi's Laboratories anticipates strong growth opportunities, especially in contrast media, sartans, and soon-to-expire patent products. - Custom synthesis business shows robust growth; 2 large projects are now at full production, expected to contribute more in coming quarters. - Nutraceutical segment growing at 10-15%, with dominant position in complex carotenoids like astaxanthin. - Stable generic API demand with good volume trends, despite current pricing pressures. - Pricing pressure and inventory cycles in generics expected to stabilize within 2 years. - New product filings (DMFs) expected to fuel growth beyond FY 2025. - Expansion of Unit 3 underway; production beginning Q1 FY '25 expected to support volume growth. - Peptide building blocks business progressing well, aiming to become a major supplier soon. - Overall, double-digit like-for-like growth YoY anticipated excluding COVID-related sales.

- Divi’s Laboratories anticipates numerous growth opportunities, particularly in contrast media, sartans, and products with soon-to-expire patents (Page 3). - Custom synthesis projects have gone into full-scale production; results from these will be visible in coming quarters, signaling growth in this segment (Pages 6, 7). - Contrast media (iodine-based) products are growing well; gadolinium-based product supplies expected to start picking up in FY 2025 (Page 8). - Despite pricing pressures in generics, volume growth and new DMFs filed are expected to contribute to growth beyond FY 2025 (Pages 4, 8). - Inventory destocking and pricing pressure cycles typically last up to 2 years, with an expected subsequent recovery (Page 14). - Unit 3 production commencement expected in Q1 FY 2025 will increase operational capacity and support growth (Page 5). - Overall, double-digit like-to-like growth was reported excluding COVID portfolio, indicating sustained strong future earnings potential (Page 5).

- Divi's Laboratories has two major custom synthesis projects with big pharma, both fully on production and contributing to strong growth. - The company has received billion-dollar scale orders from CDMOs for peptide building blocks and related reagents, signaling a substantial opportunity starting light in 2025. - The contrast media segment is progressing, with iodine-based products growing well and gadolinium-based products in the final development and approval stages, expected to pick up in fiscal 2025. - The Kakinada greenfield project is under construction and set to start production in Q1 FY 2025, enabling capacity expansion and freeing up existing facilities for new projects. - Molnupiravir sales remain significant but specific current orderbook figures for this or other products are not disclosed due to confidentiality agreements. - Overall, the orderbook reflects a diversified spread across multiple therapeutic segments and long-term growth engines with robust pipeline visibility.